Geron Corporation

GERN ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item Jun 2026 Mar 2026 Dec 2025 Sep 2025 Jun 2025 Mar 2025 Dec 2024 Sep 2024
Operating Activities
Net Income $-16.7M $-3.6M $-28.9M $-18.4M $-16.4M $-19.8M $-25.4M $-26.4M
Depreciation & Amortization $136.0K $134.0K $87.0K $128.0K $128.0K $131.0K $142.0K $31.0K
Depreciation — — — — — — — —
Amortization — — — — — — — —
Stock-Based Compensation $4.9M $4.9M $5.8M $6.7M $6.8M $7.4M $6.8M $6.9M
Net Cash from Operating Activities $-15.8M $-62.9M $-22.1M $-13.6M $-27.4M $-48.0M $-43.9M $-58.9M
Investing Activities
Capital Expenditures — — — — — — $-141.0K $0
Business Acquisitions — — — — — — — —
Net Cash from Investing Activities $8.3M $51.9M $21.1M $13.3M $20.3M $52.4M $-103.5M $-554.0K
Financing Activities
Dividends Paid — — — — — — — —
Stock Repurchases — — — — — — — —
Net Cash from Financing Activities $1.4M $2.4M $378.0K $542.0K $1.1M $256.0K $166.2M $3.6M
Net Change in Cash $-6.2M $-8.7M $-553.0K $389.0K $-6.0M $4.7M $18.7M $-55.9M
Free Cash Flow — — — — — — $-43.8M $-58.9M
← Newer Page 1 of 8 Older →